...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Dual CD44 and folate receptor-targeted nanoparticles for cancer diagnosis and anticancer drug delivery
【24h】

Dual CD44 and folate receptor-targeted nanoparticles for cancer diagnosis and anticancer drug delivery

机译:靶向CD44和叶酸受体的双重纳米颗粒可用于癌症诊断和抗癌药物递送

获取原文
获取原文并翻译 | 示例
           

摘要

Dual CD44 and folate receptor targetable nanoparticles (NPs) based on hyaluronic acid-ceramide-folic acid (HACE-FA) were fabricated for improving tumor targetability. HACE-FA was synthesized via esterification between the carboxylic group of FA and hydroxyl group of HA. Doxorubicin (DOX)-loaded HACE-FA NPs, with a mean diameter of 120-130 nm, narrow size distribution, and negative zeta potential, were prepared. The drug release from HACE-FA NPs were significantly increased in acidic pH (pH 5.5) compared with physiological pH (7.4) (p < 0.05). The cellular accumulation of the drug in HACE-FA NPs group was higher than that of HACE NPs group in SKOV-3 cells (human ovarian cancer cells; CD44 and folate receptor (FR)-positive cells). Dual targetability of HACE-FA NPs, compared to HACE NPs, was also verified in the SKOV-3 tumor-xenografted mouse model by near-infrared fluorescence (NIRF) imaging. Twenty-four hours after injection, HACE-FA NPs were accumulated mainly in tumor regions and their fluorescence intensity was 4.82-fold higher than that of HACE NPs (p < 0.05). These findings suggest successful application of HACE-FA NPs for the accurate delivery of anticancer drugs to ovarian cancer. (C) 2016 Elsevier B.V. All rights reserved.
机译:制备了基于透明质酸-神经酰胺-叶酸(HACE-FA)的双重CD44和叶酸受体靶向纳米颗粒(NPs),以提高肿瘤靶向性。 HACE-FA是通过FA的羧基与HA的羟基之间的酯化反应合成的。制备了具有阿霉素(DOX)的HACE-FA NP,平均直径为120-130 nm,尺寸分布窄,ζ电位为负。与生理pH(7.4)相比,酸性pH(pH 5.5)从HACE-FA NPs释放的药物显着增加(p <0.05)。 HACE-FA NPs组中该药物的细胞蓄积高于SKOV-3细胞(人卵巢癌细胞; CD44和叶酸受体(FR)阳性细胞)中HACE NPs组的蓄积。通过近红外荧光(NIRF)成像,在SKOV-3肿瘤异种移植小鼠模型中也证实了与HACE NPs相比,HACE-FA NPs的双重靶向性。注射后二十四小时,HACE-FA NPs主要聚集在肿瘤区域,其荧光强度是HACE NPs的4.82倍(p <0.05)。这些发现表明,HACE-FA NPs成功应用于抗癌药物向卵巢癌的准确递送。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号